CN117279657A - 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物 - Google Patents

用于治疗或预防伴随抗癌剂给药的障碍的医药组合物 Download PDF

Info

Publication number
CN117279657A
CN117279657A CN202280033165.1A CN202280033165A CN117279657A CN 117279657 A CN117279657 A CN 117279657A CN 202280033165 A CN202280033165 A CN 202280033165A CN 117279657 A CN117279657 A CN 117279657A
Authority
CN
China
Prior art keywords
cancer
disorder
sod
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033165.1A
Other languages
English (en)
Chinese (zh)
Inventor
乔志伟
本田爱美
秋元匠太
佐佐木友树
梶纪子
福田耕一郞
水岛彻
田中健一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Musashino University
LTT Bio Pharma Co Ltd
Original Assignee
Musashino University
LTT Bio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musashino University, LTT Bio Pharma Co Ltd filed Critical Musashino University
Publication of CN117279657A publication Critical patent/CN117279657A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280033165.1A 2021-05-18 2022-05-17 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物 Pending CN117279657A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-083610 2021-05-18
JP2021083610 2021-05-18
PCT/JP2022/020473 WO2022244757A1 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Publications (1)

Publication Number Publication Date
CN117279657A true CN117279657A (zh) 2023-12-22

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033165.1A Pending CN117279657A (zh) 2021-05-18 2022-05-17 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物

Country Status (11)

Country Link
US (1) US20240261375A1 (https=)
EP (1) EP4353251A4 (https=)
JP (1) JP7504367B2 (https=)
KR (1) KR102843447B1 (https=)
CN (1) CN117279657A (https=)
AU (1) AU2022278242B2 (https=)
CA (1) CA3220333A1 (https=)
CO (1) CO2023017275A2 (https=)
MX (1) MX2023013777A (https=)
TW (1) TWI867299B (https=)
WO (1) WO2022244757A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Ｌｔｔバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
ES2375797T3 (es) 2003-01-21 2012-03-06 Genervon Biopharmaceuticals Llc Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización.
JP4958556B2 (ja) * 2004-10-12 2012-06-20 株式会社Ｌｔｔバイオファーマ レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
US20100143321A1 (en) * 2006-12-19 2010-06-10 Ltt Bio Pharma Co., Ltd. Therapeutic composition for interstitual pneumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Ｌｔｔバイオファーマ 慢性閉塞性肺疾患改善剤
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
RU2017106172A (ru) 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
US11197862B2 (en) 2015-07-16 2021-12-14 Xomics Biopharma, Inc. Methods of preventing toxicity of platinum drugs
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックＩｐマネジメント株式会社 照明制御装置及び照明システム

Also Published As

Publication number Publication date
EP4353251A1 (en) 2024-04-17
US20240261375A1 (en) 2024-08-08
JP7504367B2 (ja) 2024-06-24
AU2022278242B2 (en) 2024-11-14
CO2023017275A2 (es) 2023-12-20
MX2023013777A (es) 2023-12-04
TW202313100A (zh) 2023-04-01
WO2022244757A1 (ja) 2022-11-24
KR20240008844A (ko) 2024-01-19
JPWO2022244757A1 (https=) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
TWI867299B (zh) 2024-12-21
AU2022278242A1 (en) 2023-11-30
EP4353251A4 (en) 2025-05-14
KR102843447B1 (ko) 2025-08-06
CA3220333A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
Qiao et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan
Hu et al. E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
US11622990B2 (en) VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor
US9163063B2 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
CN106565825A (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
Gao et al. The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT
EP3263107B1 (en) Block copolymer conjugate of physiologically active substance
Wei et al. Proanthocyanidin capsules remodel the ROS microenvironment via regulating MAPK signaling for accelerating diabetic wound healing
Li et al. A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy
CN117279657A (zh) 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物
US12448624B2 (en) Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
RU2451509C1 (ru) Противоопухолевый препарат
Jing et al. Natural polyphenol-loaded cross-linked lipoic acid vesicles treat triple-negative breast cancer by cancer cell killing and metastasis inhibition
Wei et al. Supramolecular self-assembling IGF-1 nanofibers modulate neutrophil extracellular traps to accelerate diabetic wound healing
RU2845522C2 (ru) Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства
HK40100859A (zh) 用於治疗或预防伴随抗癌剂给药的障碍的医药组合物
Xie et al. Engineered charge adaptive nanoplatform overcomes the drug penetration barriers to potentiate the efficacy of chemotherapy
BR112023024140B1 (pt) Uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer
US9034829B1 (en) pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
US20200206313A1 (en) Polypeptide nanotubes linked by disulfide bonds for targeted delivery of cytotoxic therapies
EP3996733A1 (en) A peptoid-peptide hybrid, nmeg-acgrp, and its use in cardiovascular diseases
JP6889458B2 (ja) 細胞増殖抑制剤
CN112294829A (zh) 红景天苷在制备治疗或预防癌症的药物中的应用
Lin Development of Targeted Pro-angiogenic Therapies for Ischemic Diabetic Foot Ulcer Repair

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100859

Country of ref document: HK